Literature DB >> 16041007

Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.

Daniel F Hoft1, Chris S Eickhoff.   

Abstract

It has been hypothesized that optimal vaccine immunity against mucosally invasive, intracellular pathogens may require the induction of different types of immune responses in mucosal and systemic lymphoid tissues. Mucosal type 2/3 responses (producing interleukin-4 [IL-4], IL-6 and/or transforming growth factor beta) could be necessary for optimal induction of protective secretory immunoglobulin A responses. On the other hand, systemic type 1 responses (including gamma interferon [IFN-gamma], tumor necrosis factor alpha, and optimal cytotoxic T-cell responses) are likely to be critical for protection against the disseminated intracellular replication that occurs after mucosal invasion. Despite these predictions, we recently found that vaccines inducing highly polarized type 1 immunity in both mucosal and systemic tissues provided optimal mucosal and systemic protection against the protozoan pathogen Trypanosoma cruzi. To further address this important question in a second model system, we now have studied the capacity of knockout mice to develop protective immune memory. T. cruzi infection followed by nifurtimox treatment rescue was used to immunize CD4, CD8, beta2-microglobulin, inducible nitric oxide synthase (iNOS), IL-12, IFN-gamma, and IL-4 knockout mice. Despite the previously demonstrated importance of CD4(+) T cells, CD8(+) T cells, and nitric oxide for T. cruzi immunity, CD4, CD8, and iNOS knockout mice developed mucosal and systemic protective immunity. However, IL-12, IFN-gamma, and beta2-microglobulin-deficient mice failed to develop mucosal or systemic protection. In contrast, IL-4 knockout mice developed maximal levels of both mucosal and systemic immune protection. These results strongly confirm our earlier conclusion from studies with polarizing vaccination protocols that type 1 immunity provides optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041007      PMCID: PMC1201214          DOI: 10.1128/IAI.73.8.4934-4940.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.

Authors:  Detlef Stober; Ieva Jomantaite; Reinhold Schirmbeck; Jörg Reimann
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

2.  Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.

Authors:  D F Hoft; C S Eickhoff
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

3.  Canarypox vaccines induce antigen-specific human gammadelta T cells capable of interferon-gamma production.

Authors:  S Worku; G J Gorse; R B Belshe; D F Hoft
Journal:  J Infect Dis       Date:  2001-07-26       Impact factor: 5.226

4.  During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein.

Authors:  Malcolm S Duthie; Monika Wleklinski-Lee; Sherilyn Smith; Toshinori Nakayama; Masaru Taniguchi; Stuart J Kahn
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  Antigen-specific Th1 but not Th2 cells provide protection from lethal Trypanosoma cruzi infection in mice.

Authors:  S Kumar; R L Tarleton
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

6.  DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene.

Authors:  A E Fujimura; S S Kinoshita; V L Pereira-Chioccola; M M Rodrigues
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

7.  Regulation of mucosal B cell immunoglobulin secretion by intestinal epithelial cell-derived cytokines.

Authors:  M E Goodrich; D W McGee
Journal:  Cytokine       Date:  1998-12       Impact factor: 3.861

Review 8.  Understanding the function of CD1-restricted T cells.

Authors:  Michael S Vincent; Jenny E Gumperz; Michael B Brenner
Journal:  Nat Immunol       Date:  2003-06       Impact factor: 25.606

9.  Oxygen-dependent microbicidal systems of phagocytes and host defense against intracellular protozoa.

Authors:  R M Locksley; S J Klebanoff
Journal:  J Cell Biochem       Date:  1983       Impact factor: 4.429

10.  Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.

Authors:  Anita R Schnapp; Chris S Eickhoff; Donata Sizemore; Roy Curtiss; Daniel F Hoft
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more
  23 in total

1.  Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.

Authors:  Nicole L Sullivan; Christopher S Eickhoff; Xiuli Zhang; Olivia K Giddings; Thomas E Lane; Daniel F Hoft
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

2.  ECG detection of murine chagasic cardiomyopathy.

Authors:  Christopher S Eickhoff; Cade T Lawrence; John E Sagartz; Leesa A Bryant; Arthur J Labovitz; Simil S Gala; Daniel F Hoft
Journal:  J Parasitol       Date:  2010-08       Impact factor: 1.276

3.  Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.

Authors:  Paula Ordonhez Rigato; Bruna C de Alencar; José Ronnie C de Vasconcelos; Mariana R Dominguez; Adriano F Araújo; Alexandre V Machado; Ricardo T Gazzinelli; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

4.  Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.

Authors:  Matthew H Collins; Julie M Craft; Juan M Bustamante; Rick L Tarleton
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

5.  Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection.

Authors:  Christopher S Eickhoff; Olivia K Giddings; Nobuko Yoshida; Daniel F Hoft
Journal:  Mem Inst Oswaldo Cruz       Date:  2010-08       Impact factor: 2.743

6.  Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.

Authors:  O K Giddings; C S Eickhoff; T J Smith; L A Bryant; D F Hoft
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

7.  Deficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion.

Authors:  Nicole L Sullivan; Christopher S Eickhoff; John Sagartz; Daniel F Hoft
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

8.  Specific humoral immunity versus polyclonal B cell activation in Trypanosoma cruzi infection of susceptible and resistant mice.

Authors:  Marianne A Bryan; Siobhan E Guyach; Karen A Norris
Journal:  PLoS Negl Trop Dis       Date:  2010-07-06

9.  Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.

Authors:  Eduardo L V Silveira; Carla Claser; Filipe A B Haolla; Luiz G Zanella; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

10.  Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.

Authors:  Bruna C G de Alencar; Pedro M Persechini; Filipe A Haolla; Gabriel de Oliveira; Jaline C Silverio; Joseli Lannes-Vieira; Alexandre V Machado; Ricardo T Gazzinelli; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.